JP2014514927A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014514927A5 JP2014514927A5 JP2014504319A JP2014504319A JP2014514927A5 JP 2014514927 A5 JP2014514927 A5 JP 2014514927A5 JP 2014504319 A JP2014504319 A JP 2014504319A JP 2014504319 A JP2014504319 A JP 2014504319A JP 2014514927 A5 JP2014514927 A5 JP 2014514927A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- antigen
- specific
- administered
- dendritic cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 19
- 238000000034 method Methods 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 210000004443 dendritic cell Anatomy 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 230000000735 allogeneic effect Effects 0.000 claims 5
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 5
- 210000004698 lymphocyte Anatomy 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 4
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 3
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000037452 priming Effects 0.000 claims 3
- 102000006306 Antigen Receptors Human genes 0.000 claims 2
- 108010083359 Antigen Receptors Proteins 0.000 claims 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 108090000172 Interleukin-15 Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 108010002586 Interleukin-7 Proteins 0.000 claims 2
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 229940124614 TLR 8 agonist Drugs 0.000 claims 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 229940022511 therapeutic cancer vaccine Drugs 0.000 claims 2
- 102000004121 Annexin A5 Human genes 0.000 claims 1
- 108090000672 Annexin A5 Proteins 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 1
- -1 IL-1β Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000005975 antitumor immune response Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161474904P | 2011-04-13 | 2011-04-13 | |
| US61/474,904 | 2011-04-13 | ||
| PCT/EP2012/056661 WO2012140130A1 (en) | 2011-04-13 | 2012-04-12 | Method for proliferation of antigen-specific t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017049576A Division JP6207783B2 (ja) | 2011-04-13 | 2017-03-15 | 抗原特異的ｔ細胞の増殖のための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014514927A JP2014514927A (ja) | 2014-06-26 |
| JP2014514927A5 true JP2014514927A5 (https=) | 2015-05-07 |
Family
ID=45937382
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504319A Pending JP2014514927A (ja) | 2011-04-13 | 2012-04-12 | 抗原特異的ｔ細胞の増殖のための方法 |
| JP2017049576A Expired - Fee Related JP6207783B2 (ja) | 2011-04-13 | 2017-03-15 | 抗原特異的ｔ細胞の増殖のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017049576A Expired - Fee Related JP6207783B2 (ja) | 2011-04-13 | 2017-03-15 | 抗原特異的ｔ細胞の増殖のための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9476028B2 (https=) |
| EP (1) | EP2697367B1 (https=) |
| JP (2) | JP2014514927A (https=) |
| KR (1) | KR102028340B1 (https=) |
| CN (1) | CN103502439B (https=) |
| WO (1) | WO2012140130A1 (https=) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5825966B2 (ja) * | 2011-10-11 | 2015-12-02 | 株式会社日本バイオセラピー研究所 | Ｃｄ５６陽性ｔ細胞増強方法 |
| EP2913394B1 (en) * | 2012-12-18 | 2016-06-22 | Immunicum AB | Co-differentiation and activation of monocytes from allogeneic donors to provide pro-inflammatory dendritic cells |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CN106103711A (zh) | 2013-11-21 | 2016-11-09 | 组库创世纪株式会社 | T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用 |
| WO2015157636A1 (en) | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
| CA2945320A1 (en) | 2014-04-10 | 2015-10-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Drug regulated transgene expression |
| NZ725201A (en) * | 2014-04-25 | 2018-05-25 | Bluebird Bio Inc | Improved methods for manufacturing adoptive cell therapies |
| LT3134432T (lt) | 2014-04-25 | 2020-04-10 | Bluebird Bio, Inc. | Mnd promotorius chimerinių antigenų receptoriams |
| SI3151672T1 (sl) | 2014-06-06 | 2021-03-31 | Bluebird Bio, Inc. | Izboljšani T-celični sestavki |
| MX2017001079A (es) | 2014-07-24 | 2017-09-12 | Bluebird Bio Inc | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). |
| MX389823B (es) * | 2014-10-27 | 2025-03-20 | Fred Hutchinson Cancer Center | Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva. |
| CN104593325A (zh) * | 2014-12-09 | 2015-05-06 | 深圳源正细胞医疗技术有限公司 | 诱导dc成熟并分泌高浓度促炎因子的方法 |
| EA036379B1 (ru) | 2014-12-12 | 2020-11-02 | Блубёрд Био, Инк. | Химерные антигенные рецепторы к bcma |
| US10544392B2 (en) * | 2015-05-01 | 2020-01-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| CA2982614A1 (en) | 2015-05-07 | 2016-11-10 | Baylor College Of Medicine | Dendritic cell immunotherapy |
| CN107750271B (zh) * | 2015-05-13 | 2021-12-10 | 泰尔茂比司特公司 | 细胞扩增 |
| US10639329B2 (en) * | 2015-06-12 | 2020-05-05 | Lentigen Technology, Inc. | Method to treat cancer with engineered T-cells |
| WO2017024006A1 (en) * | 2015-08-03 | 2017-02-09 | The Johns Hopkins University | Personalized, allogeneic cell therapy of cancer |
| WO2017027291A1 (en) | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| US11479755B2 (en) | 2015-12-07 | 2022-10-25 | 2Seventy Bio, Inc. | T cell compositions |
| EP3397263B1 (en) * | 2015-12-30 | 2023-09-20 | Celgene Corporation | T lymphocyte production methods and t lymphocytes produced thereby |
| WO2017120481A1 (en) * | 2016-01-08 | 2017-07-13 | Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center | Geriatric car-t cells and uses thereof |
| KR102770425B1 (ko) * | 2016-02-08 | 2025-02-18 | 고쿠리츠다이가쿠호진 미에다이가쿠 | 면역체크포인트 저해제 저항성 종양에 대한 t세포 수주요법의 전처치약 |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| ES2886631T3 (es) | 2016-04-15 | 2021-12-20 | Univ Kyoto | Método para inducir células T positivas para CD8 específicas de antígeno |
| CA3022267A1 (en) | 2016-05-04 | 2017-11-09 | Fred Hutchinson Cancer Research Center | Cell-based neoantigen vaccines and uses thereof |
| JP7185530B2 (ja) | 2016-06-13 | 2022-12-07 | トルク セラピューティクス， インコーポレイテッド | 免疫細胞機能を促進するための方法および組成物 |
| MA45491A (fr) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| CN107779433A (zh) * | 2016-08-30 | 2018-03-09 | 天津市康婷生物工程有限公司 | 便捷的刺激nk细胞增殖和分化的饲养层制备方法 |
| JP2018042481A (ja) * | 2016-09-13 | 2018-03-22 | テラ株式会社 | 抗原特異的ｔ細胞含有組成物及びその製造方法 |
| MX2019004707A (es) | 2016-10-26 | 2019-08-12 | Iovance Biotherapeutics Inc | Reestimulacion de linfocitos infiltrantes de tumor crioconservados. |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| KR20240005168A (ko) | 2016-11-04 | 2024-01-11 | 2세븐티 바이오, 인코포레이티드 | 항-bcma car t 세포 조성물 |
| US11401507B2 (en) | 2016-11-17 | 2022-08-02 | Iovance Biotherapeutics, Inc. | Remnant tumor infiltrating lymphocytes and methods of preparing and using the same |
| BR112019011065A2 (pt) | 2016-12-03 | 2019-10-01 | Juno Therapeutics Inc | métodos para determinação da dosagem de células t car |
| AU2017370644A1 (en) | 2016-12-05 | 2019-06-13 | Juno Therapeutics, Inc. | Production of engineered cells for adoptive cell therapy |
| CN110291200B (zh) | 2016-12-12 | 2024-05-14 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体 |
| CA3049165A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| WO2018195339A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| CN107502589A (zh) * | 2017-08-04 | 2017-12-22 | 北京世纪劲得生物技术有限公司 | 一种肿瘤浸润淋巴细胞与单个核细胞共培养方法 |
| JP7285828B2 (ja) | 2017-09-05 | 2023-06-02 | トルク セラピューティクス， インコーポレイテッド | 治療用タンパク質組成物ならびにその作製および使用方法 |
| US20210198372A1 (en) | 2017-12-01 | 2021-07-01 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
| SG11202006541UA (en) | 2018-01-08 | 2020-08-28 | Iovance Biotherapeutics Inc | Processes for generating til products enriched for tumor antigen-specific t-cells |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| WO2019183924A1 (en) * | 2018-03-30 | 2019-10-03 | Syz Cell Therapy Co. | Improved multiple antigen specific cell therapy methods |
| WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| CN108841792A (zh) * | 2018-06-14 | 2018-11-20 | 浙江大学 | 靶向cd19和ebna1基因修饰的t细胞及其制备方法与应用 |
| TW202039830A (zh) | 2018-11-05 | 2020-11-01 | 美商艾歐凡斯生物治療公司 | 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途 |
| CN109370987A (zh) * | 2018-11-23 | 2019-02-22 | 见多视光(北京)科技有限公司 | 外周血ctl细胞改良的培养方法 |
| AU2020283030A1 (en) * | 2019-05-31 | 2021-12-23 | Modernatx, Inc. | Expanded T cell assay |
| AU2020311877B2 (en) * | 2019-07-05 | 2024-01-04 | Case Western Reserve University | Priming media and methods for stem cell culture and therapy |
| AU2021217003A1 (en) | 2020-02-04 | 2022-09-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-dinitrophenol chimeric antigen receptors |
| US12091681B2 (en) * | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| CN116133679A (zh) | 2020-06-30 | 2023-05-16 | 门德斯有限公司 | 白血病衍生细胞在卵巢癌疫苗中的用途 |
| US20230372397A1 (en) | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| CN113234674B (zh) * | 2021-03-15 | 2023-02-07 | 青岛华赛伯曼医学细胞生物有限公司 | 一种t细胞活化扩增的方法及其应用 |
| AU2022246174A1 (en) | 2021-03-25 | 2023-09-14 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
| CA3248034A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT |
| CN114601923B (zh) * | 2022-04-25 | 2023-08-22 | 福建医科大学孟超肝胆医院(福州市传染病医院) | 一种新生抗原组合物及在制备治疗肿瘤的药物中的应用 |
| WO2025212473A1 (en) * | 2024-04-01 | 2025-10-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods to identify and selectively expand tumor antigen-specific t cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6821778B1 (en) * | 1993-12-01 | 2004-11-23 | The Board Of Trustees Of Leland Stanford Junior University | Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| ATE428769T1 (de) * | 1997-10-27 | 2009-05-15 | Univ Rockefeller | Methode und zusammensetzung zur herstellung von reifen dendritischen zellen |
| WO2006065495A2 (en) * | 2004-11-24 | 2006-06-22 | Fred Hutchinson Cancer Research Center | Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens |
| JP5816627B2 (ja) * | 2009-10-27 | 2015-11-18 | イミュニカム・エイビイ | 抗原特異的ｔ細胞の増殖のための方法 |
-
2012
- 2012-04-12 EP EP12713167.0A patent/EP2697367B1/en active Active
- 2012-04-12 JP JP2014504319A patent/JP2014514927A/ja active Pending
- 2012-04-12 KR KR1020137029248A patent/KR102028340B1/ko not_active Expired - Fee Related
- 2012-04-12 WO PCT/EP2012/056661 patent/WO2012140130A1/en not_active Ceased
- 2012-04-12 CN CN201280018193.2A patent/CN103502439B/zh not_active Expired - Fee Related
- 2012-04-12 US US14/110,901 patent/US9476028B2/en active Active
-
2016
- 2016-10-24 US US15/331,924 patent/US9789174B2/en active Active
-
2017
- 2017-03-15 JP JP2017049576A patent/JP6207783B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014514927A5 (https=) | ||
| CA2796379A1 (en) | Method for proliferation of antigen-specific t cells | |
| EP2696894B1 (en) | Method for priming of t cells | |
| JP2014511704A5 (https=) | ||
| KR102028340B1 (ko) | 항원-특이적 t 세포의 증식 방법 | |
| JP6022667B2 (ja) | 炎症性ヒトＴｈ１７細胞の増殖および機能を決定的に調節するＩＣＯＳ | |
| EP1930414B1 (en) | Method for activation treatment of antigen-presenting cell | |
| Liu et al. | Induction on differentiation and modulation of bone marrow progenitor of dendritic cell by methionine enkephalin (MENK) | |
| JP6697076B2 (ja) | ウイルス抗原特異的ｔ細胞の濃縮および拡大方法 | |
| KR102121492B1 (ko) | 면역치료를 사용하는 il-12의 유도 | |
| Li et al. | Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells | |
| JP2010265327A (ja) | 癌抗原非特異的な標的化ｔ細胞の製造方法及び医薬 | |
| CN113444688B (zh) | 用于抗病毒抗肿瘤的人树突状细胞诱导方法及组合物 | |
| RU2520091C2 (ru) | Способ стимуляции цитотоксического иммунного ответа против клеток опухолевой линии аденокарциномы молочной железы, экспрессирующих специфические антигены, с помощью дендритных клеток, трансфецированных полиэпитопной днк-конструкцией | |
| RU2012116602A (ru) | Способ пролиферации антигенспецифических т-клеток | |
| Foster et al. | Ex-vivo uses and applications of cytokines for adoptive immunotherapy in cancer | |
| Song et al. | Irradiated Liver Cancer Cell Vaccine Transfected With GM‐CSF Induces Specific and Long‐Lasting Anti‐tumour Immunity Through the Synergistic Effect of Oxidised mtDNA and GM‐CSF | |
| US10030227B2 (en) | Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes | |
| Mohamed et al. | In Vitro Generated Tumor/APC Hybrids Induce Allogeneic Tumor-Killer T Cells | |
| De Bruijn et al. | ANTIGEN BY MURINE DENDRITIC CELLS FOR PRESENTATION TO CYTOTOXIC T LYMPHOCYTES | |
| Hatoya et al. | WS/PP-071-04 Effect of interferon-gamma on immune and clinical responses in dendritic cell-based immunotherapy against cancer K. Sugiura1, K. Mito1, K. Ueda1, T. Hori1, T. Akazawa2, J. Yamate1 | |
| de Pagter et al. | Fast B-And NK-, Reconstitution Early After Unrelated Cord Blood Transplantation Compared To (UN) Related Bone Marrow Transplantation In Children | |
| Leen et al. | Multivirus-Specific T Cell Immunotherapy To Prevent Or Treat Infections Of Allogeneic Stem Cell Transplant Recipients | |
| HK1168869B (en) | Method for proliferation of antigen-specific t cells |